| 1 |
Fontanellas A, Avila MA. Hydroxymethylbilane synthase (aka porphobilinogen deaminase): A novel metabolic tumor suppressor gene in hepatocellular carcinoma. J Hepatol 2022;77:912-4. [PMID: 35798130 DOI: 10.1016/j.jhep.2022.06.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Longo M, Paolini E, Meroni M, Dongiovanni P. Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution. Biomedicines 2022;10:648. [DOI: 10.3390/biomedicines10030648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Córdoba KM, Serrano-Mendioroz I, Jericó D, Merino M, Jiang L, Sampedro A, Alegre M, Corrales F, Garrido MJ, Martini PGV, Lanciego JL, Prieto J, Berraondo P, Fontanellas A. Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria. Sci Transl Med 2022;14:eabc0700. [PMID: 35020410 DOI: 10.1126/scitranslmed.abc0700] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 4 |
Verma N, Thapa K, Kanojia N, Dureja H, Dua K. Advanced drug delivery systems targeting metabolic disorders: erythropoietic protoporphyria. Drug Delivery Systems for Metabolic Disorders 2022. [DOI: 10.1016/b978-0-323-99616-7.00024-4] [Reference Citation Analysis]
|
| 5 |
Shahryari A, Nazari Z, Jazi MS, Hashemi-shahraki F, Wißmiller K, Xu W, Burtscher I, Lickert H. Gene Therapy. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00213-9] [Reference Citation Analysis]
|
| 6 |
de Souza PVS, Badia BML, Farias IB, Pinto WBVR, Oliveira ASB. Acute Hepatic Porphyria: Pathophysiological Basis of Neuromuscular Manifestations. Front Neurosci 2021;15:715523. [PMID: 34646118 DOI: 10.3389/fnins.2021.715523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 7 |
Longo M, Paolini E, Meroni M, Duca L, Motta I, Fracanzani AL, Di Pierro E, Dongiovanni P. α-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study. Diagnostics (Basel) 2021;11:1628. [PMID: 34573969 DOI: 10.3390/diagnostics11091628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 8 |
Jericó D, Córdoba KM, Jiang L, Schmitt C, Morán M, Sampedro A, Alegre M, Collantes M, Santamaría E, Alegre E, Culerier C, de Mendoza AE, Oyarzabal J, Martín MA, Peñuelas I, Ávila MA, Gouya L, Martini PGV, Fontanellas A. mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks. Mol Ther Nucleic Acids 2021;25:207-19. [PMID: 34458006 DOI: 10.1016/j.omtn.2021.05.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Berger M, Lechanteur A, Evrard B, Piel G. Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now? Int J Pharm 2021;605:120851. [PMID: 34217823 DOI: 10.1016/j.ijpharm.2021.120851] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 10 |
Cui H, Zhu X, Li S, Wang P, Fang J. Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation. ACS Omega 2021;6:16259-65. [PMID: 34235295 DOI: 10.1021/acsomega.1c01755] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 11 |
Souza PVS, Badia BML, Farias IB, Gonçalves EA, Pinto WBVR, Oliveira ASB. Acute hepatic porphyrias for the neurologist: current concepts and perspectives. Arq Neuropsiquiatr 2021;79:68-80. [PMID: 33656101 DOI: 10.1590/0004-282X20200096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 12 |
Halloy F, Iyer PS, Ghidini A, Lysenko V, Barman-Aksözen J, Grubenmann CP, Jucker J, Wildner-Verhey van Wijk N, Ruepp MD, Minder EI, Minder AE, Schneider-Yin X, Theocharides APA, Schümperli D, Hall J. Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria. Cell Chem Biol 2021:S2451-9456(21)00106-9. [PMID: 33756123 DOI: 10.1016/j.chembiol.2021.02.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 13 |
Holm A, Løvendorf MB, Kauppinen S. Development of siRNA Therapeutics for the Treatment of Liver Diseases. Methods Mol Biol 2021;2282:57-75. [PMID: 33928570 DOI: 10.1007/978-1-0716-1298-9_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Thapar M, Rudnick S, Bonkovsky HL. Givosiran, a novel treatment for acute hepatic porphyrias. Expert Review of Precision Medicine and Drug Development 2021;6:9-18. [DOI: 10.1080/23808993.2021.1838275] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 15 |
Zhao L, Wang X, Zhang X, Liu X, Ma N, Zhang Y, Zhang S. Therapeutic strategies for acute intermittent porphyria. Intractable Rare Dis Res 2020;9:205-16. [PMID: 33139979 DOI: 10.5582/irdr.2020.03089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 16 |
Scott LJ. Givosiran: First Approval.Drugs. 2020;80:335-339. [PMID: 32034693 DOI: 10.1007/s40265-020-01269-0] [Cited by in Crossref: 165] [Cited by in F6Publishing: 172] [Article Influence: 55.0] [Reference Citation Analysis]
|
| 17 |
Elsaid MI, Li Y, Catalano C, Minacapelli CD, Gupta K, Rustgi VK. Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States. Pharmacoecon Open 2021;5:89-100. [PMID: 32897528 DOI: 10.1007/s41669-020-00229-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 18 |
Parra-Guillen ZP, Fontanellas A, Jiang L, Jericó D, Martini P, Vera-Yunca D, Hard M, Guey LT, Troconiz IF. Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies. Br J Pharmacol 2020;177:3168-82. [PMID: 32133631 DOI: 10.1111/bph.15040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
Rad N, Beydoun SR; Neuromuscular Division, Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, Neuromuscular Division, Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Porphyria-induced Recurrent Quadriplegia Misdiagnosed as Guillain–Barré Syndrome. US Neurology 2020;16:66. [DOI: 10.17925/usn.2020.16.1.66] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
